Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14193248 | 0.83 | ALDH1A1 (0.59) | GAAALDH1A1CYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL29212757 | 0.81 | ELANE (0.50) | GAAALDH1A1LMNARECQLMEN1 | |
| SCHEMBL12471113 | 0.80 | L3MBTL1 (0.48) | GAAALDH1A1CYP1A2CYP2C9MAPT | |
| SCHEMBL4349429 | 0.78 | ALDH1A1 (0.51) | ALDH1A1LMNA | |
| SCHEMBL10548122 | 0.78 | ALDH1A1 (0.38) | GAAALDH1A1CYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL2177419 | 0.77 | ALDH1A1 (0.50) | GAAALDH1A1CYP1A2CYP2C9MAPT | |
| SCHEMBL208184 | 0.75 | MGLL (0.31) | — | |
| SCHEMBL8087936 | 0.75 | ALDH1A1 (0.44) | GAAALDH1A1CYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL28686006 | 0.75 | NPC1 (0.32) | ALDH1A1 | |
| SCHEMBL30753838 | 0.75 | NPC1 (0.32) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3395814-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20210347756-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2021-11-11 | — | — | US | disclosed |
| US-10875837-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200109127-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2020-04-09 | — | — | US | disclosed |
| US-10221154-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| EP-3395814-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | Blueprint Medicines Corporation (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-06-22 | — | — | US | disclosed |
| US-9434700-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION | 2016-09-06 | — | — | US | disclosed |
| EP-3060560-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | Blueprint Medicines Corporation (US) | 2016-08-31 | — | — | EP | disclosed |
| US-20150119405-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-30 | — | — | US | disclosed |
| WO-2015061572-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109127-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | GAA 726/4885ALDH1A1 1963/4885CYP1A2 4597/4885 |
| US-20210347756-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | GAA 726/4885ALDH1A1 1963/4885CYP1A2 4597/4885 |
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | GAA 726/4885ALDH1A1 1963/4885CYP1A2 4597/4885 |
| US-10875837-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR4, FGFR1, FGFR2 | GAA 726/4885ALDH1A1 1963/4885CYP1A2 4597/4885 |
| US-20150119405-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | GAA 726/4885ALDH1A1 1963/4885CYP1A2 4597/4885 |
| US-10221154-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR4, FGFR1, FGFR2 | GAA 726/4885ALDH1A1 1963/4885CYP1A2 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.